OPIANT PHARMACEUTICALS INCORPORATED (OTCMKTS:OPNT) had a decrease of 43.75% in short interest. OPNT’s SI was 900 shares in April as released by FINRA. Its down 43.75% from 1,600 shares previously. With 6,200 avg volume, 0 days are for OPIANT PHARMACEUTICALS INCORPORATED (OTCMKTS:OPNT)’s short sellers to cover OPNT’s short positions. It closed at $6.55 lastly. It is down 21.46% since September 21, 2016 and is downtrending. It has underperformed by 31.89% the S&P500.
Analysts expect Sapiens International Corporation N.V. (NASDAQ:SPNS) to report $0.10 EPS on May, 9.They anticipate $0.01 EPS change or 9.09% from last quarter’s $0.11 EPS. SPNS’s profit would be $4.28M giving it 29.18 P/E if the $0.10 EPS is correct. After having $0.11 EPS previously, Sapiens International Corporation N.V.’s analysts see -9.09% EPS growth. It closed at $11.67 lastly. It is down 12.39% since September 21, 2016 and is downtrending. It has underperformed by 22.82% the S&P500.
Sapiens International Corporation N.V. is a well-known provider of software solutions for the insurance industry, with a focus on the financial services sector. The company has market cap of $499.14 million. The Firm operates in well-known provider of software solutions segment. It has a 29.76 P/E ratio. The Company’s software solutions portfolio consists of Life, Pension, Annuity and Retirement Solutions, including software solutions for the management of a range of products for life, pension, annuity and retirement; Property and Casualty/General Insurance Solutions, including a software suite of solutions, supporting a range of business lines, including personal, commercial and specialty lines, as well as a solution for the management of reinsurance contracts; Sapiens DECISION, which is a business decision management solution, and Technology-Based Solutions, such as Sapiens eMerge.
Among 4 analysts covering Sapiens Int’l (NASDAQ:SPNS), 2 have Buy rating, 1 Sell and 1 Hold. Therefore 50% are positive. Sapiens Int’l had 5 analyst reports since August 7, 2015 according to SRatingsIntel. The firm earned “Neutral” rating on Thursday, November 5 by TH Capital. The rating was downgraded by Roth Capital to “Sell” on Wednesday, May 11. The stock of Sapiens International Corporation N.V. (NASDAQ:SPNS) has “Buy” rating given on Friday, August 7 by Needham. As per Thursday, November 5, the company rating was downgraded by Roth Capital.
Opiant Pharmaceuticals, Inc., formerly Lightlake Therapeutics, Inc., is a specialty pharmaceutical company. The company has market cap of $13.05 million. The Firm develops pharmacological treatments for substance use, addictive and eating disorders. It has a 1.56 P/E ratio. The Firm has developed NARCAN Nasal Spray, a treatment to reverse opioid overdoses, which was conceived, licensed, developed and approved by the United States Food and Drug Administration (FDA).
